Ed two models. Model 1 was constructed using variables with P
Test for trends. The Cox proportional hazards regression model was used to control for multiple factors simultaneously and to estimate adjusted hazard ratios (HRs) and 95 confidence intervals. The relative increase in the risk of breast cancer recurrence for each of the three higher quartiles was estimated in comparison to that for the lowest quartile; it was also used to test for a linear trend
Test for trends. The Cox proportional hazards regression model was used to control for multiple factors simultaneously and to estimate adjusted hazard ratios (HRs) and 95 confidence intervals. The relative increase in the risk of breast cancer recurrence for each of the three higher quartiles was estimated in comparison to that for the lowest quartile; it was also used to test for a linear trend
Was fitted. The Cox proportional hazards assumptions were checked and the analyses were stratified by tumor size and ESR1 to meet the proportional hazards assumption. In a second block, the contributions of DC-SCRIPT and ESR2 (as continuous or dichotomized variables) were investigated. bWith quantitative polymerase chain reaction cut point for positive versus negative ESR1 and PGR, 0.2 and 0.1, re
Ship between DC-SCRIPT mRNA levels measured in primary breast cancers and tumor aggressiveness in a much larger, independent, breast cancer cohort. The main clinical endpoints for assessing the prognostic value of DC-SCRIPT expression were disease-free survival (DFS), metastasis-free survival (MFS), and overall survival (OS) in lymph node-negative (LNN) patients who had not received adjuvant syste
Ship between DC-SCRIPT mRNA levels measured in primary breast cancers and tumor aggressiveness in a much larger, independent, breast cancer cohort. The main clinical endpoints for assessing the prognostic value of DC-SCRIPT expression were disease-free survival (DFS), metastasis-free survival (MFS), and overall survival (OS) in lymph node-negative (LNN) patients who had not received adjuvant syste
The Reporting Recommendations for Tumor Marker Prognostic Studies guidelines [11]. The primary breast tumors were from patients with detailed clinical follow-up as previously described [12-14]. ER protein status was determined by routine ligand-binding assays or enzyme immunoassays [15], and ESR1, ESR2, and PGR mRNA status wasTissue processing, RNA isolation, cDNA synthesis, and quantitative RT-PC
Ship between DC-SCRIPT mRNA levels measured in primary breast cancers and tumor aggressiveness in a much larger, independent, breast cancer cohort. The main clinical endpoints for assessing the prognostic value of DC-SCRIPT expression were disease-free survival (DFS), metastasis-free survival (MFS), and overall survival (OS) in lymph node-negative (LNN) patients who had not received adjuvant syste